New drug combo tested for Tough-to-Treat cancers
NCT ID NCT04892017
Summary
This early-stage study is testing a new drug called DCC-3116, both by itself and combined with other cancer drugs, for people with advanced solid tumors that have specific genetic changes. The main goals are to find safe doses and see if the treatments can shrink tumors. It is for adults with cancers like non-small cell lung cancer who have already tried standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NEXT Oncology
Austin, Texas, 78758, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792, United States
-
Washington University Siteman Cancer Center
St Louis, Missouri, 63108, United States
Conditions
Explore the condition pages connected to this study.